GLP‑1 drugs linked to weight loss and lower kidney failure risk in bipolar patients
GLP‑1 medications help bipolar patients lose weight and may reduce kidney failure risk.
Key facts
- Mayo Clinic researchers found GLP‑1 use associated with lower dialysis or transplant risk in bipolar adults with chronic kidney disease.
- The study used TriNetX data from 131 million adults across 117 health systems.
- GLP‑1 users had reduced risk compared with DPP‑4 or RAAS inhibitor users.
- GLP‑1 drugs also linked to significant weight loss in other populations.
- Structured support such as apps or medically tailored meals can slow weight regain after stopping GLP‑1.
According to MedicalXpress, Mayo Clinic researchers reported that GLP‑1 receptor agonists were linked to a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.
The observational study analyzed de‑identified electronic health records from TriNetX, focusing on patients newly started on a GLP‑1 medication or a comparison treatment.
GLP‑1 users were compared with patients taking DPP‑4 inhibitors or RAAS inhibitors, and statistical matching was used to balance the groups.
The analysis followed outcomes for up to five years and found a lower risk of dialysis or transplant across both comparisons.
According to Healthline, GLP‑1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) are associated with significant weight loss in people with overweight or obesity, with an average loss of 4.1% over three months in a real‑world study.
The study included 194 adults with an average baseline weight of 221.6 pounds and BMI of 34.5, and after three months of oral semaglutide, participants lost an average of 8.8 pounds.
Healthline also reported that structured support, including a digital weight management app or medically tailored meals, may help slow weight regain after stopping GLP‑1 medications.
The small study published in Obesity Science & Practice involved 39 adults who had lost more than 10% of their weight while on GLP‑1 and had stopped treatment within 30 days.
Participants who received either the app or meal intervention regained significantly less weight over four months than those receiving usual care.
The study suggests that ongoing support can aid weight maintenance after GLP‑1 discontinuation.
Context
GLP‑1 receptor agonists are medications originally developed for type 2 diabetes and now used for weight management. They have been studied for potential kidney benefits in people with chronic kidney disease. The recent studies focus on patients with bipolar disorder, a group at higher risk for kidney problems.
How outlets headlined it
How this was made
Compiled by our AI newsroom from 2 independent outlets, checked by a separate AI editor against the sources. Only claims found in the sources are reported. Spot an error? Every source is linked below.
Correction or source request? simoneggert16@gmail.com
Open reader debate: Factual contributions and additions are synchronized directly in real time across all readers.
Loading contributions from cloud server…
Reader Discussion & Community Notes